drugset / Trial / NCT02600130

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

NCT02600130

Phase 1 Completed 33 enrolled Longeveron Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed Alzheimer's disease.

Timeline

Start
2016-10-10
Primary completion
2020-09
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy 2e+07 cells Intravenous
Subject Mesenchymal stem cell Cell therapy 1e+08 cells Intravenous

Indications